Prostate Cancer

Paradigm Shift: Radiation a New Standard in Prostate Cancer with Low Metastatic Burden

Phoebe Starr

December 2018, Vol 8, No 12 - Prostate Cancer

For patients with newly diagnosed metastatic prostate ­cancer, current standard management is androgen-deprivation therapy plus docetaxel (Taxotere). Contrary to previous assumptions, radiation to the primary tumor improves survival in men with low metastatic disease burden. This new finding came from the preplanned analysis of the multiarm, multistage STAMPEDE study presented at the ESMO 2018 Congress by lead investigator Chris C. Parker, MD, FRCR, MRCP, Consultant Clinical Oncologist, Royal Marsden NHS Foundation Trust, Sutton, England. The study was simultaneously published online in the Lancet.1 [ Read More ]

Active Surveillance the Least Costly Management Strategy for Low-Risk Prostate Cancer

Wayne Kuznar

April 2018, Vol 8, No 4 - Prostate Cancer

San Francisco, CA—Active surveillance is less costly than immediate treatment of low-risk prostate cancer, regardless of the specific treatment, according to findings from a cost analysis at a single institution presented at the 2018 Genitourinary Cancers Symposium. The cost-effectiveness of initial active surveillance compared with immediate treatment, as well as mitigation of treatment-related side effects, supports consideration of active surveillance as a management strategy in value-based care models, said lead investigator Franklin Gaylis, MD, FACS, Medical Director, Genesis Healthcare Partners (GHP), San Diego, who presented the study results. [ Read More ]

Apalutamide and Enzalutamide Each Delays Prostate Cancer Metastasis by Approximately 2 Years

Phoebe Starr

April 2018, Vol 8, No 4 - GU Cancers Symposium Highlights, Prostate Cancer

In 2 separate studies, apalutamide (Erleada) and enzalutamide (Xtandi) reduced the risk for metastasis and prolonged metastasis-­free survival in patients with nonmetastatic castrate-resistant prostate cancer (CRPC), according to the results of 2 clinical trials presented at the 2018 Genitourinary Cancers Symposium. [ Read More ]

Zytiga Receives New Indication, with Prednisone, for Metastatic, High-Risk Castration-Sensitive Prostate Cancer

March 2018, Vol 8, No 3 - FDA Approvals, News & Updates, Prostate Cancer

On February 7, 2018, abiraterone acetate (Zytiga; Janssen Biotech) received FDA approval for use, in combination with prednisone, for the treatment of patients with metastatic, high-risk castration-sensitive prostate cancer (CSPC). The FDA approved this new indication under its priority review program. [ Read More ]